The IDH3G Knockout A-549 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from the human A-549 lung adenocarcinoma line, featuring targeted disruption of the IDH3G gene. The polyclonal format ensures a heterogeneous pool that avoids clonal bias and preserves genetic diversity, offering a robust model for investigating IDH3G-dependent mitochondrial biology in lung cancer.
The A-549 cell line, originating from adenocarcinomic human alveolar basal epithelium, is a widely used non-small cell lung cancer (NSCLC) model. It maintains epithelial morphology and metabolic hallmarks of adenocarcinoma, including active oxidative phosphorylation and TCA cycle function, providing a clinically relevant backdrop for studying mitochondrial enzyme roles in tumor metabolism and drug response.
IDH3G encodes the gamma subunit of IDH3, a heterotetrameric enzyme that catalyzes NAD+-dependent conversion of isocitrate to alpha-ketoglutarate (??-KG). This reaction is a major source of mitochondrial NADH and a critical node linking TCA cycle flux to electron transport (via Complex I) and epigenetic regulation (via ??-KG-dependent TET and JMJD demethylases). IDH3G assembly into the IDH3 complex requires IDH3A and IDH3B, and its transcription is promoted by the PGC-1??/ERR??/NRF1 axis. Disruption of IDH3G impairs NADH and ??-KG production, thereby reducing electron transport chain activity and diminishing ??-KG availability for chromatin remodeling.
In A-549 cells, IDH3G knockout heightens metabolic vulnerability by compromising mitochondrial NADH generation, potentially driving a shift toward glycolysis or glutamine utilization. Reduced ??-KG levels may also impair TET- and JMJD-mediated demethylation, altering epigenetic landscapes and influencing proliferation and differentiation. This model is thus particularly valuable for examining how TCA cycle deficiencies affect cancer cell fitness, metabolic adaptation, and sensitivity to metabolism-targeting agents.
Key applications encompass cancer metabolism studies, mitochondrial respiration assays (Seahorse), TCA cycle metabolite profiling, and drug sensitivity screening. Researchers can use Western blotting and RT-qPCR to confirm target disruption and monitor effectors such as PGC-1??, proliferation assays to gauge growth under metabolic stress, and drug panels to identify synthetic lethal relationships. The IDH3G Knockout A-549 Polyclonal Cells provide a powerful, disease-relevant system for dissecting mitochondrial metabolism in lung adenocarcinoma and for preclinical testing of metabolic therapeutics. Contact Ascent Research for further information.
